Welcome to our dedicated page for Integer Holdings news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Holdings stock.
Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Integer (NYSE: ITGR) announced its executive leadership will participate in three investor conferences in March 2026: Raymond James (11:35 a.m. ET, March 3), Oppenheimer (12:40 p.m. ET, March 17) and KeyBanc (11:15 a.m. ET, March 18).
According to Integer, each event will be available via live webcast and replay under Investor Relations > News & Events at investor.integer.net.
Integer (NYSE:ITGR) reported fourth-quarter and full-year 2025 results on Feb 19, 2026, with 2025 sales of $1.854 billion (up 8%) and adjusted EPS of $6.40 (up 21%). Integer generated $196 million of operating cash flow, repurchased ~698,356 shares for $50 million, and ended 2025 with $1.185 billion total debt (leverage 3.0x).
The company maintained its 2026 outlook midpoint, targeting adjusted EPS $6.29–$6.78 and reiterated a plan to return to ~200 bps above-market organic sales growth by 2027.
Integer (NYSE: ITGR) will exhibit at MD&M West 2026 in Anaheim, Feb 3–5, unveiling an expanded 20 x 50 sq. ft. booth #3201 and showcasing R&D Velocity, an integrated R&D ecosystem linking design, prototyping and manufacturing to accelerate device manufacturability.
Integer will also highlight expanded medical coatings capabilities after recent acquisitions, plus cardiac rhythm, neuromodulation, and cardio/vascular product platforms.
Integer (NYSE: ITGR) will webcast a conference call to discuss fourth quarter and full year results for the period ended Dec. 31, 2025, on Thursday, Feb. 19, 2026 at 8 a.m. CT / 9 a.m. ET.
The company will issue a news release with financial results prior to the call. Domestic dial-in: (800) 715-9871; international dial-in: (646) 307-1963; conference ID: 3120125. Webcast registration is available via the Integer investor site and an audio replay will be available for seven days by dialing (800) 770-2030 or (609) 800-9909 using the same conference ID. Live and archived replay will be on Integer's Investor Relations website.
Integer (NYSE: ITGR) will exhibit at the North American Neuromodulation Society Annual Meeting in Las Vegas from Jan. 22–25, 2026. Visit booth #115 to see Integer’s work on neuromodulation and miniaturized active implantable medical devices (AIMDs) aimed at accelerating development timelines and reducing risk for device makers.
Integer will highlight full-system capabilities—from high-performance batteries to integrated implantable pulse generators and lead systems—and showcase the Xcellion® Gen 3 Fast Charge Lithium Ion battery, which offers best-in-class runtime and recharges in as little as 30 minutes.
Integer (NYSE: ITGR) said members of its executive leadership team will participate in two investor conferences in early December 2025.
Scheduled appearances: Piper Sandler 37th Annual Healthcare Conference at 8:00 a.m. ET on Tuesday, Dec. 2, 2025, and Citi 2025 Global Healthcare Conference at 9:45 a.m. ET on Wednesday, Dec. 3, 2025. Live webcasts and replays will be available under News & Events in the Investor Relations section at investor.integer.net.
Integer Holdings Corporation (NYSE: ITGR) announced on November 4, 2025 that its Board authorized a $200 million share repurchase program for the company's outstanding common stock. The company said it intends to primarily use cash on hand and free cash flows to fund repurchases. Management may execute repurchases opportunistically or under trading plans, and timing and volume will be at management's discretion. The Board and management characterized the program as reflecting confidence in Integer's strategy and financial position.
Integer (NYSE: ITGR) announced that Payman Khales has assumed the role of President and Chief Executive Officer and joined the company's Board, effective Oct 24, 2025, completing a planned transition announced in April 2025.
Khales joined Integer in 2018, doubled Cardio & Vascular sales in seven years while improving service and profitability, and most recently served as Chief Operating Officer overseeing both business units and global operations. He succeeds Joseph Dziedzic, who is retiring after eight years as CEO and will remain an advisor through Mar 31, 2026 to support the transition.
Integer (NYSE:ITGR) reported third quarter 2025 results for the period ended September 26, 2025, with sales of $467.7M (+8% YoY; organic +7%) and GAAP operating income of $56M. Non-GAAP results showed adjusted operating income $86M (+14%), adjusted EBITDA $106M (+11%), and adjusted EPS $1.79 (+25%).
Total debt rose by $204M to $1.194B, producing a leverage ratio of 3.0x adjusted EBITDA. Product-line drivers included Cardio & Vascular +15% Q and Cardiac Rhythm & Neuromodulation +2% Q; Other Markets fell ~16% Q due to a planned exit. The company updated 2025 guidance and provided preliminary 2026–2027 outlooks, including 2025 sales of $1.84–1.854B and adjusted EPS of $6.29–6.43.
Integer Holdings (NYSE:ITGR) has scheduled its third quarter 2025 earnings conference call for Thursday, October 23, 2025, at 8 a.m. CT / 9 a.m. ET. The company will release its Q3 2025 financial results prior to the call on the same day.
The conference call will be accessible via webcast and telephone, with domestic dial-in at (800) 715-9871 and international dial-in at (646) 307-1963 using Conference ID 3120125. An audio replay will be available for seven days following the call.